Physician profile
Lyra D Ng
NPI 1316989932
$1,671.18
in general payments reported to CMS, 2019-2025
15 companies · $174 in 2025
The $174 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $227 · 2021: $316 · 2022: $147 · 2023: $294 · 2024: $250 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $718.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $484.88 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $312.78 | 2019-2023 | |
| Glaxosmithkline, LLC. | $231.03 | 2019-2025 | Bexsero, Shingrix, Arexvy |
| Gilead Sciences, INC. | $172.25 | 2019-2023 | Vemlidy |
| Janssen Pharmaceuticals, INC | $128.87 | 2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Cranial Technologies, INC | $49.99 | 2021-2025 | Doc Band |
| Lilly USA, LLC | $34.21 | 2020 | |
| Xeris Pharmaceuticals, INC. | $23.81 | 2025 | Gvoke Hypopen |
| Dynavax Technologies Corporation | $20.23 | 2019 | |
| Sanofi Pasteur INC. | $18.80 | 2025 | |
| Dexcom, INC. | $18.58 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.15 | 2024 | Jardiance |
| Modernatx, INC. | $16.98 | 2025 | Mresvia |
| Astrazeneca Pharmaceuticals LP | $16.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lyra Ng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.